Loading stock data…
Guardant Health (GH)
$147.33-2.87 (-1.91%)
Market ClosedLast close Jul 24
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Guardant Health, Inc. in the Healthcare sector is trading at $147.33 with a market capitalization of $17.3B. Wall Street consensus targets $171.08 (24 analysts), implying a +16.1% move over the next 12 months. The stock is currently 15% below its 52-week high of $174.08, remaining 40.1% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +16.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 31) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $301.67M↑ | $281.27M↑ | $265.20M↑ | $232.09M↑ | $203.47M |
| Gross Profit | $196.75M↑ | $181.77M↑ | $171.61M↑ | $150.88M↑ | $128.75M |
| Operating Income | -$121.35M↓ | -$120.81M↓ | -$98.99M↑ | -$106.41M↑ | -$111.04M |
| Net Income | -$112.08M↑ | -$128.49M↓ | -$92.72M↑ | -$99.90M↓ | -$95.16M |
Peer Comparison
JNJUNHPFE
Fundamentals
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liqu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$17.29B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
239.24%
Volume
Today's trading volume
1.88M
Recent News
Apple Stock Shines As Earnings Approach, But Remaining Magnificent 6 Stumble With Nasdaq
Apple stock is holding up the best out of the Magnificent Seven stocks as the company has proceeded cautiously with its AI investments.
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strong Results Boosted Guardant Health (GH) in Q2
Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States […]
Alamar Hits A High Note On Alzheimer's Buzz
If you’re an Alamar Biosciences (ALMR) shareholder, Friday was a good day. The stock climbed +7.3%, closing the session at a new 52-week high of $28.42. That’s a tidy gain on a day when the S&P 500 barely nudged up +0.4% and some key industry peers actually lost ground.
Freenome colorectal cancer test data improve on earlier results
The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.